Abivax S.a.

This study tested a daily pill called ABX464 in 217 adults with moderate to severe ulcerative colitis who had already completed 16 weeks of treatment. The goal was to see if the drug could keep the disease in remission for up to 96 weeks. Researchers measured remission using a st…

This study tested an experimental daily pill called ABX464 in 355 adults with moderate to severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could reduce symptoms like diarrhea, bleeding, and colon inflammation compared to a …

This study looked at the long-term safety of a drug called ABX464 in 40 adults with moderate to severe rheumatoid arthritis. All participants had already completed a 12-week treatment course. The goal was to see if taking the drug for up to 52 more weeks was safe and helped keep …

This study tested a new daily pill, ABX464, in 636 adults with moderate-to-severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could help achieve remission and improve the lining of the colon after 8 weeks, compared to a place…

This study tested a daily pill called ABX464 in 639 adults and teens with moderate to severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could safely help patients achieve remission (symptom relief and bowel healing) after 8 …